VISEN Pharmaceuticals (HKG:2561)

Market Cap	1.52B -63.8%
Revenue (ttm)	39.32M +3,950.1%
Net Income	-276.50M
EPS	-2.55
Shares Out	109.30M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28,100
Open	13.50
Previous Close	14.00
Day's Range	12.87 - 15.01
52-Week Range	12.87 - 43.30
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 27, 2026

About VISEN Pharmaceuticals

VISEN Pharmaceuticals, an investment holding company, engages in the development and commercialization of paradigm-shifting endocrine therapies in the Chinese Mainland. The company’s lead product, Lonapegsomatropin, a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency. It also develops TransCon CNP (navepegritide), a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia, that is in phase 2 clinical trial; and Palopegteriparatide, a once-daily parath...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2018
• Employees: 102
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2561

Financial Performance

In 2025, VISEN Pharmaceuticals's revenue was 136,000, a decrease of -95.10% compared to the previous year's 2.78 million. Losses were -253.42 million, 39.1% more than in 2024.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 30, 2026

Data Sources Report a data error